| 1. |
- Bernasconi, Anna, et al.
(författare)
-
From model checking to a temporal proof for partial models
- 2017
-
Ingår i: Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics). - Cham : Springer International Publishing. - 1611-3349 .- 0302-9743. ; 10469 LNCS, s. 54-69
-
Konferensbidrag (refereegranskat)abstract
- Three-valued model checking has been proposed to support verification when some portions of the model are unspecified. Given a formal property, the model checker returns true if the property is satisfied, false and a violating behavior if it is not, maybe and a possibly violating behavior if it is possibly satisfied, i.e., its satisfaction may depend on how the unspecified parts are refined. Model checking, however, does not explain the reasons why a property holds, or possibly holds. Theorem proving can instead do it by providing a formal proof that explains why a property holds, or possibly holds in a system. Integration of theorem proving with model checking has only been studied for classical two-valued logic – hence, for fully specified models. This paper proposes a unified approach that enriches three-valued model checking with theorem proving to generate proofs which explain why true and maybe results are returned.
|
|
| 2. |
- McMahon, J. H., et al.
(författare)
-
Neurotoxicity with high-dose disulfiram and vorinostat used for HIV latency reversal
- 2022
-
Ingår i: Aids. - : Ovid Technologies (Wolters Kluwer Health). - 0269-9370 .- 1473-5571. ; 36:1, s. 75-82
-
Tidskriftsartikel (refereegranskat)abstract
- Objective: The aim of this study was to examine whether administering both vorinostat and disulfiram to people with HIV (PWH) on antiretroviral therapy (ART) is well tolerated and can enhance HIV latency reversal. Design: Vorinostat and disulfiram can increase HIV transcription in PWH on ART. Together, these agents may lead to significant HIV latency reversal. Methods: Virologically suppressed PWH on ART received disulfiram 2000 mg daily for 28 days and vorinostat 400 mg daily on days 8-10 and 22-24. The primary endpoint was plasma HIV RNA on day 11 relative to baseline using a single copy assay. Assessments included cell-associated unspliced RNA as a marker of latency reversal, HIV DNA in CD4(+) T-cells, plasma HIV RNA, and plasma concentrations of ART, vorinostat, and disulfiram. Results: The first two participants (P1 and P2) experienced grade 3 neurotoxicity leading to trial suspension. After 24 days, P1 presented with confusion, lethargy, and ataxia having stopped disulfiram and ART. Symptoms resolved by day 29. After 11 days, P2 presented with paranoia, emotional lability, lethargy, ataxia, and study drugs were ceased. Symptoms resolved by day 23. CA-US RNA increased by 1.4-fold and 1.3-fold for P1 and P2 respectively. Plasma HIV RNA was detectable from day 8 to 37 (peak 81 copies ml(-1)) for P2 but was not increased in P1 Antiretroviral levels were therapeutic and neuronal injury markers were elevated in P1. Conclusion: The combination of prolonged high-dose disulfiram and vorinostat was not safe in PWH on ART and should not be pursued despite evidence of latency reversal.
|
|
